The short version of peptide agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-24 and is reviewed periodically as new material appears.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Important musical rhythms of the Andean Region are the danza (dance of Andean folklore arising from the transformation of the European contredance), the bambuco (it is played with guitar, tiple and mandolin, the rhythm is danced by couples), the pasillo (a rhythm inspired by the Austrian waltz and the Colombian "danza", the lyrics have been composed by well-known poets), the guabina (the tiple, the bandola and the requinto are the basic instruments), the sanjuanero (it originated in Tolima and Huila Departments, the rhythm is joyful and fast). Apart from these traditional rhythms, salsa music has spread throughout the country, and the city of Cali is considered by many salsa singers to be 'The New Salsa Capital of the World'. The instruments that distinguish the music of the Eastern Plains are the harp, the cuatro (a type of four-stringed guitar) and maracas. Important rhythms of this region are the joropo (a fast rhythm and there is also tapping as a result of its flamenco ancestry) and the galeron (it is heard a lot while cowboys are working). The music of the Amazon region is strongly influenced by the indigenous religious practices. Some of the musical instruments used are the manguaré (a musical instrument of ceremonial type, consisting of a pair of large cylindrical drums), the quena (melodic instrument), the rondador, the congas, bells, and different types of flutes. The music of the Archipelago of San Andrés, Providencia and Santa Catalina is usually accompanied by a mandolin, a tub-bass, a jawbone, a guitar and maracas.
Bronzers are a temporary sunless tanning or bronzing option. These come in powders, sprays, mousse, gels, lotions and moisturizers. Once applied, they create a tan that can easily be removed with soap and water. Like make-up, these products tint or stain a person's skin only until they are washed off. They are often used for "one-day" only tans, or to complement a DHA-based sunless tan. Many formulations are available, and some have limited sweat or light water resistance. Walnut oil extract, jojoba extract, and caramel are ingredients frequently used in temporary bronzers. If bronzer is applied under clothing, or where fabric and skin edges meet, most will create some light but visible rub-off. Dark clothing prevents the rub-off from being noticeable. While these products are much safer than tanning beds, the color produced can sometimes look orangey and splotchy if applied incorrectly. A recent trend is that of lotions or moisturizers containing a gradual tanning agent. A slight increase in color is usually observable after the first use, but color will continue to darken the more frequently the product is used. Just as with the term "sunless tanner", the term "bronzer" is likewise not defined by law, or by regulations enforced by the FDA. What is defined and regulated is the color additive DHA, or dihydroxyacetone. (Note that the "color additive" dihydroxyacetone is itself colorless.) Many of these bronzers contain allergens such as benzyl alcohol, tocopherol (vitamin E), and fragrances.
==== Kidney functions ==== The pendrin protein promotes the electroneutral exchange of tissue chloride (Cl−) for urinary bicarbonate (HCO3−) in the apical surfaces (i.e., surfaces facing the urine) of the kidney's renal β-intercalated cells (also termed type B intercalated cells) and non-α non-β intercalated cells (also termed non-A non-B intercalated cells) in the kidney's collecting duct system (i.e., CDS). A study in mice found that OXGR1 colocalizes with pendrin in the β-intercalated cells and non-α non-β intercalated cells lining the tubules of their kidney's CDS. The intercalated cells in the CDS tubules isolated from mice used pendrin in cooperation with the electroneutral sodium bicarbonate exchanger 1 protein to mediate the Cl− for HCO3− exchange. α-Ketoglutarate stimulated the rate of this exchange in CDS tubules isolated from control mice (i.e., mice that had the Oxgr1 gene and protein) but not in CDS tubules isolated from Oxgr1 gene knockout mice (i.e., mice that lacked the Oxgr1 gene and protein). This study also showed that the α-ketoglutarate in the blood of mice filtered through their kidney's glomeruli into the proximal tubules and loops of Henle where it was reabsorbed. Mice drinking water with a basic pH (i.e., >7) due to the addition of sodium bicarbonate and mice lacking the Oxgr1 gene and protein who drink water without sodium bicarbonate had urines that were more basic (i.e., pH about 7.8) and contained higher levels of urinary α-ketoglutarate than control mice drinking water without this additive.
1993/3066) International Carriage of Dangerous Goods by Road (Fees) (Amendment) Regulations 1993 (S.I. 1993/3067) International Transport of Goods under Cover of TIR Carnets (Fees) (Amendment) Regulations 1993 (S.I. 1993/3068) Children (Homes, Arrangements for Placement, Reviews and Representations) (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/3069) Education (Publication of Schemes for Financing Schools) Regulations 1993 (S.I. 1993/3070) Common Agricultural Policy (Wine) (Amendment) Regulations 1993 (S.I. 1993/3071) Education (Acquisition of Grant–maintained Status) (Transitional Functions) Regulations 1993 (S.I. 1993/3072) Education (Grant–maintained Schools) (Loans) Regulations 1993 (S.I. 1993/3073) Personal Protective Equipment (EC Directive) (Amendment) Regulations 1993 (S.I. 1993/3074) Prison (Amendment) (No. 2) Rules 1993 (S.I. 1993/3075) Young Offender Institution (Amendment) Rules 1993 (S.I. 1993/3076) Non–Domestic Rating Contributions (Wales) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3077) A1 Trunk Road (Holloway Road, Islington) (Prescribed Routes) Order 1993 (S.I. 1993/3078) Fire Services (Appointments and Promotion) (Scotland) Amendment Regulations 1993 (S.I. 1993/3079) Act of Sederunt (Fees of Solicitors in the Sheriff Court) (Amendment and Further Provisions) 1993 (S.I. 1993/3080) Police (Scotland) Amendment Regulations 1993 (S.I. 1993/3081) Non-Domestic Rating Contributions (England) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3082) Boiler (Efficiency) Regulations 1993 (S.I.
=== Bibliography === L.L. Van Slyke; A.W. Bosworth; C.C. Hedges (December 1910). "Chemical Investigation of Best Conditions for Making the Lime-Sulfur Wash" (PDF). New York Agricultural Experiment Station Bulletin (329). Geneva, New York.
Sources: en.wikipedia.org
== Inhibitors == Proteinase K has two disulfide bonds, but it exhibits higher proteolytic activity in the presence of reducing agents (e.g. 5 mM DTT), suggesting that the presumed reduction of its own disulfide bonds does not lead to its irreversible inactivation. Proteinase K is inhibited by serine protease inhibitors such as phenylmethylsulfonyl fluoride (PMSF), diisopropylfluorophosphate (DFP), or 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF). Proteinase K activity is unaffected by the sulfhydryl modifying reagents: para-chloromercuribenzoic acid (PCMB), N-alpha-tosyl-L-lysyl-chloromethyl-ketone (TLCK), or N-alpha-Tosyl-l-phenylalanine Chloromethyl Ketone (TPCK), although presumably if these reagents were included alongside disulfide reducing reagents which exposed the typically-unavailable Proteinase K thiols, it may then become inhibited.
The Newcomb Cleveland Prize of the American Association for the Advancement of Science (AAAS) is annually awarded to author(s) of outstanding scientific paper published in the Research Articles or Reports sections of Science. Established in 1923, funded by Newcomb Cleveland who remained anonymous until his death in 1951, and for this period it was known as the AAAS Thousand Dollar Prize. "The prize was inspired by Mr. Cleveland's belief that it was the scientist who counted and who needed the encouragement an unexpected monetary award could give." The present rules were instituted in 1975, previously it had gone to the author(s) of noteworthy papers, representing an outstanding contribution to science, presented in a regular session, sectional or societal, during the AAAS Annual Meeting. It is now sponsored by the Fodor Family Trust and includes a prize of $25,000. The prize's current sponsorship has a notable connection to a past winner: Stephen P. A. Fodor, founder of Affymetrix, received the prize in 1990 for a paper introducing microarray technology. Affymetrix added its support to the prize in 2003, more than doubling its monetary value at the time. Winners receive a bronze medal, a share of the prize money, and reimbursement for travel to the AAAS Annual Meeting. Final selection is determined by a panel of distinguished scientists appointed by the editor-in-chief of Science. The annual contest period runs from the first issue of June through the last issue of the following May. No prize was awarded in 1942–1945, 1948, 1973, 1975, or 1976.
=== Secondary probing === One major difference between nitrocellulose and PVDF membranes relates to the ability of each to support "stripping" antibodies off and reusing the membrane for subsequent antibody probes. While there are well-established protocols available for stripping nitrocellulose membranes, the sturdier PVDF allows for easier stripping, and for more reuse before background noise limits experiments. Another difference is that, unlike nitrocellulose, PVDF must be soaked in 95% ethanol, isopropanol or methanol before use. PVDF membranes also tend to be thicker and more resistant to damage during use.
The first documented use of electrical stimulation for pain relief dates back to 46 AD when Scribonius Largus of the ancient Roman Empire used the electric properties of torpedo fish to relieve headaches. Scientific studies of neuromodulation began in 1745, when German physician De Haen published "a number of cases of spasmodic, paralytic and other nervous affections cured by electricity". The first implementation of electrocutical apparatus in hospital medical treatment recorded in Middlesex Hospital of London in 1767. In 1780, Italian physicist and biologist Luigi Galvani investigated how electrical signals in nerves could control muscle movement, further evidence of the electrical nature of the neuronal activity.
Sources: en.wikipedia.org
=== Aortic insufficiency === Aortic insufficiency (AI) occurs in half to two-thirds of ascending AD, and the diastolic heart murmur of aortic insufficiency is audible in about 32% of proximal dissections. The intensity (loudness) of the murmur depends on the blood pressure and may be inaudible in the event of low blood pressure. Multiple causes exist for AI in the setting of ascending AD. The dissection may dilate the annulus of the aortic valve, preventing the leaflets of the valve from coapting. The dissection may extend into the aortic root and detach the aortic valve leaflets. Alternatively, following an extensive intimal tear, the intimal flap may prolapse into the left ventricular outflow tract, causing intimal intussusception into the aortic valve, thereby preventing proper valve closure.
=== Refractory period === Each action potential is followed by a refractory period, which can be divided into an absolute refractory period, during which it is impossible to evoke another action potential, and then a relative refractory period, during which a stronger-than-usual stimulus is required. These two refractory periods are caused by changes in the state of sodium and potassium channel molecules. When closing after an action potential, sodium channels enter an "inactivated" state, in which they cannot be made to open regardless of the membrane potential—this gives rise to the absolute refractory period. Even after a sufficient number of sodium channels have transitioned back to their resting state, it frequently happens that a fraction of potassium channels remains open, making it difficult for the membrane potential to depolarize, and thereby giving rise to the relative refractory period. Because the density and subtypes of potassium channels may differ greatly between different types of neurons, the duration of the relative refractory period is highly variable. The absolute refractory period is largely responsible for the unidirectional propagation of action potentials along axons. At any given moment, the patch of axon behind the actively spiking part is refractory, but the patch in front, not having been activated recently, is capable of being stimulated by the depolarization from the action potential.
Fatoumata Binta Diallo - First woman who registered to practice law in the Bar of the Republic of Guinea Conakry. Bachir Diallo - Minister of Security and Civil Protection, Guinea. Facinet Sylla - Minister of Budget, former executive director Of International Monetary Fund. Katoucha (Kadiatou Niane) – former model and fashion designer, Guinea Boubacar Yacine Diallo – Journalist, Writer, former Minister of Communication, former chairman of the National Council of Communication, Current vice president of the independent national institution for human rights in Guinea. Addi Bâ or Bah Mamadou Hady – called by the Germans "black terrorist" ("Der schwarze Terrorist"), a figure of the French resistance, member of the first scrub of the Vosges, Guinea Aïcha Bah Diallo – former Minister of Education and Women's Rights Activist, former Senior education leader at UNESCO. Hamidou Diallo – American professional basketball player. 2019 NBA All-Star Slam Dunk Contest winner Abou Sangaré - Mechanic and Actor, Best European Actor 2024 Rabiatou Sérah Diallo – Guinean trade unionist. former president of the National Transitional Council. Current president of Economic and Social Council, Guinea Black M (Alpha Diallo) – French rapper and Singer–Songwriter.
Experts said that their findings did not challenge the conclusions by UK government: "We provided that information to the Government who have then used a number of other sources to come to the conclusions that they have." On 12 April 2018 the OPCW announced that their investigations agreed with the conclusions made by the UK about the identity of the chemical used. By September 2018, two Russian "tourists", "Alexander Petrov" and "Ruslan Boshirov", had been identified as suspects. They told Margarita Simonyan, the chief editor of RT television, in an interview that they both worked in the sports nutrition business and that: "Those are our real names.. We're afraid to go out, we fear for ourselves, our lives and lives of our loved ones." The Crown Prosecution Service announced enough evidence was obtained by that date "to convict the two men" of the attack, although it did not apply to Russia "for their extradition because Russia does not extradite its own nationals. [...] However, a European Arrest Warrant has been obtained in case they travel to the EU". In February 2019, the Bellingcat website published precise allegations that identified GRU Major Denis Vyacheslavovich Sergeev as a man who travelled in March 2018 to London under the false identity of Sergei Fedotov. It is claimed with detailed photograph evidence, and phone, travel, passport, and motoring database records that GRU Colonels Alexander Mishkin and Anatoly Chepiga assumed the identities of Petrov and Boshirov, and placed the poison on Skripal's doorknob.
=== Overdose === Overdose is extremely dangerous; cases reported to poison control centers had a 11.9 percent fatality rate between 2010 and 2020. Although the largest number of overdose deaths occurred in the 1910s and 1920s when the chemical was in more widespread industrial use, the substance's use as a dieting aid has caused a number of fatalities in the 21st century: at least 50 overdose deaths were reported worldwide between 2010 and 2020. Although the lowest published fatal ingested dose is 4.3 mg/kg, a typical overdose death occurs at a higher level of exposure, around 20–50 mg/kg. The first symptoms to appear are nausea, vomiting, abdominal pain, and perhaps diarrhea. The typical overdose syndrome seen with DNP and other phenols is a combination of hyperthermia, tachycardia, diaphoresis, and tachypnoea. Because of the heat produced during uncoupling, DNP overdose will overpower the body's attempt to maintain thermal homeostasis and cause an uncontrolled, fatal rise in body temperature up to as high as 44 °C (111 °F). The disruption of metabolism also leads to the accumulation of potassium and phosphate, potentially contributing to toxicity. DNP can cause T wave and ST segment abnormalities; heart muscle, kidney, and liver damage have been found on autopsy. According to an analysis of United Kingdom and United States overdose cases, tachycardia, hyperpyrexia, acidosis, and agitation or confusion are independent predictors of overdose death. There is no antidote to DNP and management strategies are based on expert opinion and case studies.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.